Novo Nordisk Enters $2.1 Billion Partnership with Vivtex for Oral Biologics
Novo Nordisk entered a $2.1 billion partnership with Vivtex to develop oral delivery of biologic drugs, combining Novo's peptide expertise with Vivtex's GI formulation platform.